Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases
Pharmaceutics · 02.05.2025 · 17 (5) · 606
DOI: 10.3390/pharmaceutics17050606 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 02.05.2025. Verfasst von Kannan Badri Narayanan. Beteiligte Einrichtung: School of Chemical Engineering, Yeungnam University, 280 Daehak-Ro, Gyeongsan 38541, Gyeongbuk, Republic of Korea. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 244 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Inflammation is a multifaceted biological response of the immune system against various harmful stimuli, including pathogens (such as bacteria and viruses), cellular damage, toxins, and natural/synthetic irritants. This protective mechanism is essential for eliminating the cause of injury, removing damaged cells, and initiating the repair process. While inflammation is a fundamental component of the body’s defense and healing process, its dysregulation can lead to pathological consequences, contributing to various acute and chronic diseases, such as autoimmune disorders, cancer, metabolic syndromes, cardiovascular diseases, neurodegenerative conditions, and other systemic complications. Generally, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs), antihistamines, biologics, and colchicine are used as pharmacological agents in the management of inflammatory diseases. However, these conventional treatments often have limitations, including adverse side effects, long-term toxicity, and drug resistance. In contrast, enzyme-based therapeutics have emerged as a promising alternative due to their high specificity, catalytic efficiency, and ability to modulate inflammatory pathways with reduced side effects. These enzymes function by scavenging reactive oxygen species (ROS), inhibiting cytokine transcription, degrading circulating cytokines, and blocking cytokine release by targeting exocytosis-related receptors. Additionally, their role in tissue repair and regeneration further enhances their therapeutic potential. Most natural anti-inflammatory enzymes belong to the oxidoreductase class, including catalase and superoxide dismutase, as well as hydrolases such as trypsin, chymotrypsin, nattokinase, bromelain, papain, serratiopeptidase, collagenase, hyaluronidase, and lysozyme. Engineered enzymes, such as Tobacco Etch Virus (TEV) protease and botulinum neurotoxin type A (BoNT/A), have also demonstrated significant potential in targeted anti-inflammatory therapies. Recent advancements in enzyme engineering, nanotechnology-based enzyme delivery, and biopharmaceutical formulations have further expanded their applicability in treating inflammatory diseases. This review provides a comprehensive overview of both natural and engineered enzymes, along with their formulations, used as anti-inflammatory therapeutics. It highlights improvements in stability, efficacy, and specificity, as well as minimized immunogenicity, while discussing their mechanisms of action and clinical applications and potential future developments in enzyme-based biomedical therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chemical Engineering, Yeungnam University, 280 Daehak-Ro, Gyeongsan 38541, Gyeongbuk, Republic of Korea.
- Research Institute of Cell Culture, Yeungnam University, 280 Daehak-Ro, Gyeongsan 38541, Gyeongbuk, Republic of Korea.
ORCID-Profile: Kannan Badri Narayanan
Förderung
- National Research Foundation of Korea (NRF)
Zitieren
APA
Narayanan, K. B. (2025). Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases. Pharmaceutics, 17(5), 606. https://doi.org/10.3390/pharmaceutics17050606
Vancouver
Narayanan KB. Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases. Pharmaceutics. 2025;17(5):606. doi:10.3390/pharmaceutics17050606
BibTeX
@article{Narayanan2025,
author = {Narayanan, Kannan Badri},
title = {Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {5},
pages = {606},
doi = {10.3390/pharmaceutics17050606}
}
EUVIMED